TSE:PMN

ProMIS Neurosciences (PMN) Stock Forecast, Price & News

C$6.80

+0.19 (+2.87%)

(As of 06/7/2023 ET)

Compare

Today's Range: C$6.80
▼
C$6.80
50-Day Range: C$6.35
▼
C$11.00
52-Week Range: C$5.60
▼
C$12.22

Volume: 2,599 shs
Average Volume: 1,951 shs
Market Capitalization: C$58.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Earnings Insider Trades Headlines Social Media

About ProMIS Neurosciences (TSE:PMN) Stock

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Receive PMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

PMN Stock News Headlines

May 31, 2023 | americanbankingnews.com

ProMIS Neurosciences (TSE:PMN) Trading Up 0.7%

May 16, 2023 | finanznachrichten.de

ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

June 8, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 8, 2023 | finance.yahoo.com

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease

April 27, 2023 | theglobeandmail.com

Closing Bell: Promis Neurosciences Inc up on Wednesday (PMN)

April 19, 2023 | theglobeandmail.com

Closing Bell: Promis Neurosciences Inc down on Wednesday (PMN)

April 10, 2023 | proactiveinvestors.com

ProMIS Neurosciences submits IND application for Alzheimer's treatment

April 10, 2023 | finance.yahoo.com

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

June 8, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

March 29, 2023 | finance.yahoo.com

Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

March 13, 2023 | finance.yahoo.com

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

March 13, 2023 | finance.yahoo.com

ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

January 22, 2023 | reuters.com

PMN.TO - | Stock Price & Latest News | Reuters

October 26, 2022 | seekingalpha.com

PMN:CA ProMIS Neurosciences, Inc.

October 17, 2022 | finance.yahoo.com

ProMIS Neurosciences, Inc. (PMN)

August 15, 2022 | finance.yahoo.com

Can ProMIS Neurosciences (TSE:PMN) Afford To Invest In Growth?

August 4, 2022 | financialpost.com

ProMIS Neurosciences Presents at 2022 Alzheimer's Association International Conference

August 2, 2022 | finance.yahoo.com

ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference

July 27, 2022 | finance.yahoo.com

ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference

July 15, 2022 | nasdaq.com

ProMIS Neurosciences Rings the Closing Bell

July 1, 2022 | ca.finance.yahoo.com

ProMIS at 52-Week High

June 27, 2022 | finanznachrichten.de

ProMIS Neurosciences Inc.: ProMIS Neurosciences announces reverse share split to meet NASDAQ listing criteria

June 27, 2022 | finance.yahoo.com

PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA

June 22, 2022 | ca.finance.yahoo.com

Stocks in play: ProMIS Neurosciences Inc.

May 13, 2022 | ca.finance.yahoo.com

Stocks in play: ProMIS Neurosciences Inc

May 13, 2022 | finance.yahoo.com

ProMIS Neurosciences Announces First Quarter 2022 Results

May 13, 2022 | finance.yahoo.com

ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved

See More Headlines

PMN Price History

30 days | 90 days | 365 days | Advanced Chart

PMN Company Calendar

Last Earnings: 5/15/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/11/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:PMN
Previous Symbol: TSE:AMF
CUSIP: N/A
CIK: N/A
Web: www.promisneurosciences.com
Phone: +1-416-8476898
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): C($3.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-20,930,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -837.71%
Return on Assets: -168.33%

Debt

Debt-to-Equity Ratio: 108.33
Current Ratio: 0.51
Quick Ratio: 1.30

Sales & Book Value

Annual Sales: C$7,558.00
Price / Sales: 7,719.50
Cash Flow: C$0.48 per share
Price / Cash Flow: 14.07
Book Value: C($0.72) per share
Price / Book: -9.44

Miscellaneous

Outstanding Shares: 8,580,000
Free Float: N/A
Market Cap: C$58.34 million
Optionable: Not Optionable
Beta: 1.15

Key Executives

Dr. Neil R. Cashman M.D. (Age 70)
Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
Comp: $99k

Mr. Daniel E. Geffken M.B.A. (Age 65)
MBA, Chief Financial Officer
Comp: $122.28k

Mr. Gavin T. Malenfant (Age 60)
Chief Operating Officer
Comp: $53.32k

Dr. Johanne Kaplan Ph.D.
Chief Devel. Officer

Dr. Gail M. Farfel Ph.D. (Age 58)
Chief Exec. Officer

Dr. Ernest D. Bush Ph.D.
Head of Pharmacology/Toxicology & Sr. Consultant

Dr. David Wishart Ph.D.
Chief Physics Officer

Mr. Dennis Chen Ph.D.
Head of Manufacturing & Sr. Consultant

Dr. Larry Douglas Altstiel M.D. (Age 72)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

PMN Stock - Frequently Asked Questions

How have PMN shares performed in 2023?: ProMIS Neurosciences' stock was trading at C$6.10 at the beginning of 2023. Since then, PMN shares have increased by 11.5% and is now trading at C$6.80.
View the best growth stocks for 2023 here.
When is ProMIS Neurosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our PMN earnings forecast.
How were ProMIS Neurosciences' earnings last quarter?: ProMIS Neurosciences, Inc. (TSE:PMN) posted its quarterly earnings data on Monday, May, 15th. The company reported ($0.78) earnings per share for the quarter.
What other stocks do shareholders of ProMIS Neurosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ProMIS Neurosciences investors own include CRISPR Therapeutics (CRSP), Aurora Cannabis (ACB), Biocept (BIOC), Spectra7 Microsystems (SEV), Flexion Therapeutics (FLXN), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bonavista Energy Co. (BNP.TO) (BNP) and QEP Resources (QEP).

What is ProMIS Neurosciences' stock symbol?: ProMIS Neurosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PMN."
How do I buy shares of ProMIS Neurosciences?: Shares of PMN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is ProMIS Neurosciences' stock price today?: One share of PMN stock can currently be purchased for approximately C$6.80.
How much money does ProMIS Neurosciences make?: ProMIS Neurosciences (TSE:PMN) has a market capitalization of C$58.34 million and generates C$7,558.00 in revenue each year. The company earns C$-20,930,000.00 in net income (profit) each year or C($3.70) on an earnings per share basis.
How can I contact ProMIS Neurosciences?: ProMIS Neurosciences' mailing address is 1920 Yonge St Suite 200, TORONTO, ON M4S 3E2, Canada. The official website for the company is www.promisneurosciences.com. The company can be reached via phone at +1-416-8476898.

This page (TSE:PMN) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial